Spots Global Cancer Trial Database for Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer

Official Title: Open-Label, Pilot Study of Olaparib as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer

Study ID: NCT03570476

Conditions

Prostate Adenocarcinoma Without Neuroendocrine Differentiation

Stage I Prostate Cancer AJCC v8

Stage II Prostate Cancer AJCC v8

Stage IIA Prostate Cancer AJCC v8

Stage IIB Prostate Cancer AJCC v8

Stage IIC Prostate Cancer AJCC v8

Interventions

Olaparib

Radical Prostatectomy

Study Description

Brief Summary: This phase II trial studies how well olaparib works in treating participants with prostate cancer that has not spread to other parts of the body (localized). Olaparib may stop the growth of tumor cells by interfering with the activity of a substance called PARP, which is inside cells. Giving olaparib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

Detailed Description: PRIMARY OBJECTIVE: I. To assess the pathological complete response rate following olaparib when administered as neoadjuvant therapy prior to prostatectomy in patients with localized prostate cancer containing homozygous or complementary deoxyribonucleic acid \[DNA\] repair deficiency. SECONDARY OBJECTIVE: I. To determine the rate of positive surgical margins, extracapsular extension, positive seminal vesicles and lymph nodes at the time of prostatectomy. OUTLINE: Participants receive olaparib orally twice daily for 90 days in the absence of unacceptable toxicity. Beginning 1 day after last olaparib dose, participants undergo radical prostatectomy. After completion of study treatment, participants are followed up for 30 days.